Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Published Online: 2020-05-?
Journal: The Lancet Haematology•Publisher: Elsevier BV
Authors: Christoph Heuck•Cyrille Hulin•Darrell White•Dolly A Parasrampuria•Hareth Nahi•Hila Magen•Ivan Spicka•Jacob Laubach•Joan Bladé•Kristen Lantz•Lisa O'Rourke•Maria-Victoria Mateos•Martin Kaiser•Max Flogegard•Michele Cavo•Ming Qi•Nizar Bahlis•Pamela L Clemens•Philippe Moreau•Saad Z Usmani•Sebastian Grosicki•Shinsuke Iida•Sibirina Korenkova•Steven Xu•Tara Masterson•Valerio De Stefano•Vania Hungria•Vladimir Vorobyev•Wojciech Legiec•Xiang Qin•Zhilong Yuan
